Nancy L. Lewis, MD, from the Thomas Jefferson University Hospitals, discusses the phase III CORRECT trial that examined the multitargeted tyrosine kinase inhibitor regorafenib.
Nancy L. Lewis, MD
Advertisement
Articles by Nancy L. Lewis, MD
Advertisement
Latest Updated Articles
Dr. Nancy Lewis Discusses the Regorafenib CORRECT TrialPublished: October 18th 2012 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Approves Larger Vial Size for Nelarabine Injection in T-ALL and T-LBL
5